Tag: Spdr S&P Pharmaceuticals Etf

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Biotech’s recovery isn’t a ‘head fake.’  These 3 stocks could lead the next leg up

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed